PROTEIN POLYMER TECHNOLOGIES FEAURED IN RECENT WALL STREET TRANSCRIPT REPORT
Issue focuses on companies and trends in the Medical Supply and Device industry
San Diego, CA, -- January 22, 2004 -- Protein Polymer Technologies
(Nasdaq: PPTI.OB), a Company focused on the development of high performance
bioactive devices designed for improved surgical outcomes, announced today
that its president and CEO, Dr. J. Thomas Parmeter, was recently featured
in The Wall Street Transcript's 190-page "Medical Supplies & Devices"
issue. Published
on January 12, 2004, the extensive report contains an analyst roundtable
forum, individual analyst interviews, and in-depth interviews with executives
from 19 publicly traded companies in the medical supply and device industry.
The complete interview with Dr. Parmeter will be available next week on PPTI's
website, www.ppti.com.
Topics discussed during Dr. Parmeter's interview include:
§
PPTI background including
two products in human clinicals, a third to begin human clinicals shortly,
new products in the pipeline, all based on platform technology covered by 25
U.S. patents
§
How PPTI's urethral bulking
agent should offer an alternative to surgery in the large and growing market
opportunity for the treatment of female stress urinary incontinence
§
Why PPTI's injectable hydrogel
technology for the treatment of dermal contour deficiencies should provide
longer lasting results in the rapidly expanding market for cosmetic facial
treatments, and how the product is complementary to Botox®
§
PPTI's adhesive hydrogel technology
for use in spinal disc repair, and the company's strategic relationship with
Spine Wave which it helped establish to develop and market new technology for
orthopedic applications
§
Key personnel and strategy
for growth
³"Showcasing
PPTI and our technology in The Wall Street Transcript's "Medical Supplies & Devices"
issue provides an ideal opportunity for PPTI to communicate our core messages
to
a very targeted and important audience. In particular, the investment community should find my interview
to be a valuable resource when making decisions about PPTI and the markets
that we serve," stated J. Thomas Parmeter, Ph.D., President and CEO of Protein
Polymer Technologies.
About Protein Polymer Technologies
Protein Polymer Technologies, Inc.,
is a San Diego-based company focused on developing bioactive devices to improve
medical and surgical outcomes. From
its inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices. These genetically engineered biomaterials are high molecular
weight proteins, processed into products with physical and biological characteristics
tailored to specific clinical performance requirements. Targeted products include urethral bulking
agents for the treatment of stress urinary incontinence, dermal augmentation
products for cosmetic and reconstructive surgery, surgical adhesives and
sealants, scaffolds for wound healing and tissue engineering, and depots
for local drug delivery. To
date, PPTI has been issued 25 U.S. Patents on its core technology with corresponding
issued and pending patents in key international markets.
Safe Harbor
This press release contains forward-looking statements that
are based on management's views and expectations. Actual results could differ
materially from those expressed here; further, the Company is not obligated
to comment specifically on those differences. Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up. The reader is encouraged to refer
to the Company's 2002 Annual Report Form 10-KSB, and other recent filings
with the Securities and Exchange Commission, copies of which are available
from the Company, to further ascertain the risks associated with the above
statements.
CONTACTS:
J. Thomas Parmeter, President
(858) 558-6064
jtp@ppti.com
or
Jill Meleski, AVP
The Ruth Group
(646) 536-7032
jmeleski@theruthgroup.com
